What is the Samsung Biologics Co., Ltd. stock price forecast?

Samsung Biologics Co., Ltd. is currently trading at ₩1,598,000. View real-time AI analysis on Alpha Lenz.

What is Samsung Biologics Co., Ltd. insider trading activity?

View the latest insider trading data for Samsung Biologics Co., Ltd. on Alpha Lenz.

What is Samsung Biologics Co., Ltd.'s P/E ratio?

Samsung Biologics Co., Ltd.'s P/E ratio is 103.8.

Samsung Biologics Co., Ltd.

KRX · 207940

₩1,598,000

Ask about Samsung Biologics Co., Ltd.'s future dividend policy...

Alpha Chat Insight

“Samsung Biologics Co., Ltd. trades at a P/E of 103.8 (premium valuation) with solid ROE of 10.4%. 3Y revenue CAGR of 42.6% highlights clear growth momentum.”

Ask for details →

Company Overview

Samsung Biologics Co., Ltd. is a key player in the biopharmaceutical manufacturing and services industry. Established as a subsidiary of Samsung Group, it focuses on the development and manufacturing of biologic drugs. The company provides contract development and manufacturing organization (CDMO) services, supporting pharmaceutical companies in bringing innovative treatments to market efficiently. Samsung Biologics operates through state-of-the-art facilities offering comprehensive services from cell line development to large-scale manufacturing, impacting the healthcare and biotechnology sectors significantly. Headquartered in South Korea, it plays a critical role in the global supply chain of biologics, an essential component in treating complex diseases like cancer and autoimmune disorders. The company's strategic partnerships and investments in advanced bioprocessing technologies enhance its market position as a leader in its field.

CEO임존종보 (Rim John Chongbo)

Websitehttps://samsungbiologics.com

SectorHealthcare

IndustryBiotechnology

Employees5,047

Company Statistics

FY 2024

Profile

₩112,454,920,000,000Market Cap

₩4,547,322,176,420Revenue

71.17MShares Out

5,047Employees

Margins

50.38%Gross

45.44%EBITDA

29.03%Operating

30.13%Pre-Tax

23.82%Net

Valuation

103.81P/E

10.31P/B

24.73EV/Sales

54.95EV/EBITDA

399.16P/FCF

Growth (CAGR)

42.61%Rev 3Yr

45.32%Rev 5Yr

34.93%Op Inc 3Yr

70.45%Op Inc 5Yr

40.14%Net Inc 3Yr

39.80%Net Inc 5Yr

Returns

6.49%ROA

10.45%ROE

8.51%ROIC

Financial Health

₩391,221,617,200Cash & Cash Equivalents

₩6,040,398,670,280Net Debt

58.98%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Samsung Biologics Co., Ltd. trades at a P/E of 103.8 (premium valuation) with solid ROE of 10.4%. 3Y revenue CAGR of 42.6% highlights clear growth momentum.”

Ask for details →

Frequently Asked Questions

Samsung Biologics Co., Ltd. (ticker: 207940) is a company listed on KRX in the Healthcare sector (Biotechnology). It has approximately 5,047 employees. Market cap is $112.5T.

The current price is ₩1,598,000 with a P/E ratio of 103.81x and P/B of 10.31x.

ROE is 10.45% and operating margin is 29.03%. Annual revenue is $4.5T.